Related Experiment Video
Updated: Jun 4, 2026
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
Published on: January 17, 2015
Developing Anti-HER2/neu Single-Chain Fv Fragments from Phage Display Libraries
Abstract:
One of the major failures of conventional cancer therapy has been the inability to achieve a sufficient differential in toxicity between normal and neoplastic tissues. Since hybridoma technology was established (1), monoclonal antibodies (MAbs) have been raised against a variety of tumor-associated antigens to overcome the lack of specificity. Unfortunately, MAbs have for the most part, failed to fulfill the expectations of being the desired "magic bullets" capable of directing cytotoxic effects strictly to malignant cells. The notable exception has been in the treatment of B-cell lymphomas that have exhibited an exciting response rate when treated with unconjugated (2) and radiolabeled (3) MAbs. However, similar progress has not been observed in the treatment of ovarian carcinoma and other solid malignancies. These tumors contain disordered vasculature and lack draining lymphatics, resulting in elevated interstitial pressure. In this environment, the diffusion of a relatively large, 150 kDa IgG molecule is limited to 1 mm in 2-3 d (4). In contrast, smaller molecules such as 50 kDa Fab fragments exhibit faster movement through the tumor interstitium, on the order of 1 to 2 mm per day.
Insights
Monoclonal antibodies (MAbs) show promise for B-cell lymphomas but struggle with solid tumors like ovarian cancer due to poor diffusion. Smaller antibody fragments (Fab) may offer improved tumor penetration for better cancer therapy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Conventional cancer therapies lack sufficient toxicity differential between normal and cancerous tissues.
- Monoclonal antibodies (MAbs) were developed to target tumor-associated antigens, aiming for greater specificity.
- MAbs have shown success in B-cell lymphomas but not in solid tumors like ovarian carcinoma.
Purpose of the Study:
- To investigate the limitations of MAb delivery in solid tumors.
- To explore alternative antibody formats for improved tumor penetration.
Main Methods:
- Review of MAb efficacy in different cancer types.
- Analysis of diffusion characteristics of large IgG molecules versus smaller antibody fragments (Fab) in tumor interstitial environments.
Main Results:
- MAbs have demonstrated significant efficacy in treating B-cell lymphomas.
- Solid tumors, including ovarian carcinoma, present challenges due to disordered vasculature and high interstitial pressure, limiting MAb diffusion.
- Larger IgG molecules (150 kDa) diffuse slowly (1 mm in 2-3 days), while smaller Fab fragments (50 kDa) show faster interstitial movement (1-2 mm per day).
Conclusions:
- The physical properties of solid tumors impede the effective delivery of conventional MAbs.
- Smaller antibody fragments, such as Fab, exhibit superior diffusion characteristics within the tumor interstitium.
- Further research into antibody fragments may enhance targeted cancer therapy for solid malignancies.
